bis-(3-oxo-butyl)-ether | 90113-31-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: bis-(3-oxo-butyl)-ether
• 英文别名: 3.3'-Dioxo-dibutylaether；Bis-(3-oxo-butyl)-aether；4-(3-Oxobutoxy)butan-2-one
• CAS: 90113-31-8
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: GSRSHHZXRQGIEM-UHFFFAOYSA-N

物化性质

• 沸点：
  254.4±15.0 °C(Predicted)
• 密度：
  0.981±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  bis-(3-oxo-butyl)-ether 在 diluted acid 作用下， 生成 丁烯酮
  参考文献：
  名称：

  The Effect on Attribute Prediction of Location Uncertainty in Spatial Data

  摘要：

  A datum is considered spatial if it contains location information. Typically, there is also attribute information, whose distribution depends on its location. Thus, error in location information can lead to error in attribute information, which is reflected ultimately in the inference drawn from the data. We propose a statistical model for incorporating location error into spatial data analysis. We investigate the effect of location error on the spatial lag, the covariance function, and optimal spatial linear prediction (that is, kriging). We show that the form of kriging after adjusting for location error is the same as that of kriging without adjusting for location error. However, location error changes entries in the matrix of explanatory variables, the matrix of co‐variances between the sample sites, and the vector of covariances between the sample sites and the prediction location. We investigate, through simulation, the effect that varying trend, measurement error, location error, range of spatial dependence, sample size, and prediction location have on kriging after and without adjusting for location error. When the location error is large, kriging after adjusting for location error performs markedly better than kriging without adjusting for location error, in terms of both the prediction bias and the mean squared prediction error.

  DOI：

  10.1111/j.1538-4632.2002.tb01088.x
• 作为产物：
  描述：

  4-羟基-2-丁酮 在 硫酸 作用下， 反应 48.0h， 以95%的产率得到bis-(3-oxo-butyl)-ether
  参考文献：
  名称：

  一种β-聚醚胺及其合成方法和含有其的脂肪族聚脲涂料

  摘要：

  本发明公开了一种β‑聚醚胺及其合成方法和含有其的脂肪族聚脲涂料，属于化工产品生产技术领域，β‑聚醚胺通过酮醇类化合物制得，酮醇类化合物中氧原子与仲碳原子共同组成羰基，羰基经过化学反应形成肟，肟经还原形成胺，最终得到的β‑聚醚胺中，胺基为伯胺，且位于β碳原子上，胺基活性受到邻近的甲基基团的影响，导致活性减弱，因此最终得到的脂肪族聚脲涂料适用期相对较长，可实现多样化的施工工艺，施工过程简单。

  公开号：

  CN114213264A

文献信息

• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Cerulean Pharma Inc.

  公开号：US20130196906A1

  公开（公告）日：2013-08-01

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了关于使用CDP-治疗剂偶联物治疗疾病或紊乱的方法，例如自身免疫疾病、炎症性疾病、中枢神经系统紊乱、心血管疾病或代谢紊乱。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
• MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US20170209591A1

  公开（公告）日：2017-07-27

  Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.

  本文提供了马替西酚类化合物、其衍生物、共轭物以及使用它们治疗或预防增生性疾病的方法。
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
  申请人：Ryan John

  公开号：US20110152512A1

  公开（公告）日：2011-06-23

  Methods and compositions relating to CDP-epothilone conjugates are described herein.

  本文描述了与CDP-epothilone共轭物相关的方法和组合物。
• TREATMENT OF CANCER
  申请人：Ryan John

  公开号：US20110160159A1

  公开（公告）日：2011-06-30

  Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

  提供了与含有CDP-拓扑异构酶抑制剂的组合物相关的方法，例如CDP-喜树碱或喜树碱衍生物结合物，例如CRLX101。
• COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE
  申请人：Eliasof Scott

  公开号：US20120064107A1

  公开（公告）日：2012-03-15

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了一种使用CDP-治疗药物偶联物治疗自身免疫性疾病、炎症性疾病或癌症的方法。还提供了CDP-治疗药物偶联物、包含CDP-治疗药物偶联物的粒子以及包含CDP-治疗药物偶联物的组合物。